When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they'd stumbled upon a revolutionary tool researchers could ...
CRISPR Therapeutics is obviously a biopharma name -- but it's a unique one. Co-founder Emmanuelle Charpentier and her research collaborator Jennifer Doudna co-invented the CRISPR/Cas9 gene-editing ...
In 2020, Jennifer Doudna, Ph.D., received the Nobel Prize in Chemistry, CRISPR-Cas9, a method for genome editing. Often referred to as “molecular scissors,” CRISPR cuts DNA at specific locations that ...
Researchers are investigating the potential of CRISPR in relation to Down syndrome.
Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...
When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they’d stumbled upon a revolutionary tool researchers could ...
The biotech has won approval for one of the few gene-editing therapies on the market. Several more therapies based on the same science are in the works. Like most young biopharma companies, this one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results